2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Wednesday, October 24, 2018

11:00AM-12:30PM: Abstract Number: 2955

Risk of Neurological Adverse Events during Tumour Necrosis Factor Inhibitor Treatment for Arthritis: A Population-Based Cohort Study from Danbio and the Danish National Patient Registry

6W018 ACR Abstract: Epidemiology & Pub Health IV: Determinants & Consequences of Tx (2952–2957)

11:00AM-12:30PM: Abstract Number: 2971

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease: Long Term Outcomes

6W021 ACR Abstract: Misc Rheumatic & Inflam DZ II (2970–2975)

11:00AM-12:30PM: Abstract Number: 2968

Role of Choline in Gouty Inflammation

6W020 ACR Abstract: Metabolic & Crystal Arthropathies–Basic Science & Imaging (2964–2969)

11:00AM-12:30PM: Abstract Number: 2957

Socioeconomic Differences in Opioid Use By People with Inflammatory Arthritis

6W018 ACR Abstract: Epidemiology & Pub Health IV: Determinants & Consequences of Tx (2952–2957)

11:00AM-12:30PM: Abstract Number: 2946

T Peripheral Helper Cells Are Expanded in the Circulation of Active SLE Patients and Correlate with CD21low B Cells

6W024 ACR Abstract: SLE–Etiology & Pathogenesis II (2946–2951)

11:00AM-12:30PM: Abstract Number: 2965

Targeting Glucose Metabolism in the Murine Air Pouch Model of Acute Gouty Inflammation

6W020 ACR Abstract: Metabolic & Crystal Arthropathies–Basic Science & Imaging (2964–2969)

11:00AM-12:30PM: Abstract Number: 2983

The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study

6W023 ACR Abstract: RA–DX, Manifestations, & Outcomes VI: Outcomes Reports (2982–2987)

11:00AM-12:30PM: Abstract Number: 2996

The Economic Burden of Systemic Lupus Erythematosus (SLE) within a Medicaid Cohort Stratified By Disease Severity

6W027 ACR/ARHP Abstract: Health Services Research II: Economic & Clinical Implications (2994–2999)

11:00AM-12:30PM: Abstract Number: 2986

The Impact of Exercise and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study

6W023 ACR Abstract: RA–DX, Manifestations, & Outcomes VI: Outcomes Reports (2982–2987)

11:00AM-12:30PM: Abstract Number: 2966

Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study

6W020 ACR Abstract: Metabolic & Crystal Arthropathies–Basic Science & Imaging (2964–2969)

11:00AM-12:30PM: Abstract Number: 2951

Ustekinumab Treatment Response in SLE Is Associated with Changes in Type II but Not Type I Interferons

6W024 ACR Abstract: SLE–Etiology & Pathogenesis II (2946–2951)

11:00AM-12:30PM: Abstract Number: 2993

Vascular Involvement in Behcet’s Syndrome May be Associated with Subclinical Atherosclerosis

6W025 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os III: Clinical Subtype & Outcome(2988–2993)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].